A RANGE of progenitor cells derived from healthy mouse small intestine tissue will be of particular interest to research groups using BME 2 organoid matrix and specialising in drug screening applications, says Amsbio.
The company has extended its product range in the organoid culture market with the introduction of Cultrex organoid progenitor cells.
These cells can be expanded using RGF BME-R1, and may be induced to express tissue specific markers under differentiating conditions.
They are said to be suitable for use with gene editing techniques such as Crispr/Cas9 to develop models for infectious disease and cancer, and to study the normal intestine.
Cultrex organoid progenitor cells support the development of complex models requiring multiple genomic modifications, the company adds.
It describes its organoid 3D cultures as the ‘next generation’ of tissue culture models, which are extracted directly from living tissues.
Stem cell populations are maintained using an extracellular matrix environment under non-differentiating conditions, rather than in an artificial plastic environment.